Cue Biopharma, Inc.
CUE
$0.80
$0.011.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.80% | -29.08% | -9.65% | 14.86% | 17.62% |
| Total Depreciation and Amortization | 1,461.39% | -95.08% | 245.25% | -187.59% | 1,528.28% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | -10.00% | 11.11% | 0.00% |
| Total Other Non-Cash Items | -76.06% | 411.29% | -118.15% | 266.76% | -61.96% |
| Change in Net Operating Assets | 62.61% | 302.44% | 29.17% | 48.67% | -804.38% |
| Cash from Operations | 58.21% | 9.48% | -19.94% | 24.65% | -2.11% |
| Capital Expenditure | 82.00% | -7,400.00% | -300.00% | 110.00% | 81.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -98.97% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 82.00% | -14,900.00% | -101.02% | 1,080.00% | 81.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -0.10% | 0.10% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -99.38% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,879.80% | -7.30% | -109.49% | 1,082.10% | -142.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 254.00% | 6.42% | -516.43% | 121.75% | -46.96% |